NKTR shares climb to $9.54 amid investor optimism and Phase IIb REZOLVE-AD results; EPS forecasts up 10.5% in 30 days.

US Dollar South African Rand, Nasdaq 100, S&P 500, Alphabet Inc Class A. Read 's Market Analysis on Investing.com ZA.

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Major indices closed higher on Tuesday despite Israeli claims that Iran had already breached a ceasefire agreement.

New player emerges in 23andMe bankruptcy An Indian drug company has big plans for the East Bay An Indian drug company has big ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...